Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia.

Abstract

Bacteriophage therapy is the use of viruses to kill bacteria for the treatment of antibiotic-resistant infections. Little is known about the human immune response following phage therapy. We report the development of phage-specific CD4 T cells alongside rising phage-specific immunoglobulin G and neutralizing antibodies in response to adjunctive bacteriophage therapy used to treat a multidrug-resistant Pseudomonas aeruginosa pneumonia in a lung transplant recipient. Clinically, treatment was considered a success despite the development phage-specific immune responses.

• Authors: Jennifer M Dan, Susan M Lehman, Rita Al-Kolla, Samuel Penziner, Kamyar Afshar, Gordon Yung, Eugene Golts, Nancy Law, Cathy Logan, Zsuzsanna Kovach, Gill Mearns, Robert T Schooley, Saima Aslam, Shane Crotty
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 227 Issue 3 Pg. 311-316 (02 01 2023) ISSN: 1537-6613 [Electronic] United States
• PMID: 36082999 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].

Topics

• Humans
• Bacteriophages (physiology)
• Phage Therapy
• Transplant Recipients
• Pneumonia
• Lung (microbiology)
• Immunity
• Pseudomonas aeruginosa (physiology)
• Pseudomonas Infections (therapy, microbiology)